Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

The user is considering combining finasteride and minoxidil tablets into a topical solution that already includes Garnier Fructis stemoxydine and CB0103. They are seeking advice on whether this combination is effective and safe.

The user is using a topical solution containing 1% finasteride and 5% minoxidil for hair loss, with water, glycerin, and PEG-40 hydrogenated castor oil as carrier agents. They are questioning if these ingredients are effective carriers after using the solution for three months.

The conversation provides advice on using derma rollers, stamps, and pens for hair loss, detailing types, usage, cleaning, depth, frequency, and caution with topicals like minoxidil. The user plans to replace a roller with a pen for better accuracy and safety, and uses a castor oil/rosemary oil mix post-needling.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The conversation is about finding a source for topical valproic acid for hair regrowth. The user mentions PP405 and the unavailability of products from certain suppliers.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

A user switched from a 1.5 mm derma roller to an adjustable dermastamp for microneedling to treat hair loss and found it less painful and more effective. Some users prefer different depths and tools like the Dr.Pen for microneedling, while others debate the necessity of depth and tool type.

PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

The conversation discusses adding crushed finasteride tablets to topical minoxidil, but it's advised against because the tablets are not water-soluble and meant for oral use. The suggestion is to take finasteride orally instead.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

An individual is seeking options for topical finasteride and minoxidil in Australia, considering products from Medicii Labs and exploring other suppliers. They plan to use a derma roller and caffeine + yerba mate hair wash alongside these treatments.

Dermapen is considered more effective and easier to use than dermaroller and dermastamp for hair loss treatment, though results vary. Dermastamp is affordable but less convenient, while dermapen is more precise but can be bloody.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.

The conversation is about using a dermastamp for hair loss treatment and concerns about a potentially scam product, pp405. It suggests sticking with known treatments like finasteride and minoxidil.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

Dermastamp is preferred for hair growth and skin health due to fewer scars, with recommended needle sizes of 0.5-1.5mm. Dermapen is also favored over dermarollers, which are considered dangerous.

A user is seeking topical versions of minoxidil and finasteride in Australia that do not contain propylene glycol. They are looking for alternatives due to potential irritation from propylene glycol.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

User is on vacation in Greece and wants to buy tretinoin or isotretinoin to improve Minoxidil absorption. They are considering isotretinoin since it is available over-the-counter in Greece but requires a prescription back home.

The conversation discusses hair loss treatments, specifically comparing Dr. Pen and Derminator for hair growth. The user is seeking advice on affordable options due to a low income.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.